메뉴 건너뛰기




Volumn 157, Issue 5, 2007, Pages 571-577

Optimalization and cost management of lanreotide-Autogel therapy in acromegaly

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; SOMATOMEDIN C;

EID: 36549054677     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-07-0366     Document Type: Article
Times cited : (20)

References (34)
  • 1
    • 34547651880 scopus 로고    scopus 로고
    • AACE Guidelines. American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly
    • AACE Guidelines. American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly. Endocrine Practice 2004 10 214-225.
    • (2004) Endocrine Practice , vol.10 , pp. 214-225
  • 2
    • 4744348959 scopus 로고    scopus 로고
    • Acromegaly
    • edn 2 ch. 11, pp, Ed. S Melmed, Massachusetts: Blackwell Science Inc
    • Melmed S. Acromegaly. In The Pituitary, edn 2 (ch. 11), pp 419-454. Ed. S Melmed, Massachusetts: Blackwell Science Inc, 2002.
    • (2002) The Pituitary , pp. 419-454
    • Melmed, S.1
  • 4
    • 33750069148 scopus 로고    scopus 로고
    • Is there still a role for radiotherapy in acromegaly?
    • Monson JP. Is there still a role for radiotherapy in acromegaly? Neuroendocrinology 2006 83 269-273.
    • (2006) Neuroendocrinology , vol.83 , pp. 269-273
    • Monson, J.P.1
  • 6
    • 0034836491 scopus 로고    scopus 로고
    • Efficacy of radiotherapy in normalizing serum IGF-I. acid-labile subunit (ALS) and IGFBP-3 levels in acromegaly
    • Epaminonda P, Porretti S, Cappiello V, Beck-Peccoz P, Faglia G & Arosio M. Efficacy of radiotherapy in normalizing serum IGF-I. acid-labile subunit (ALS) and IGFBP-3 levels in acromegaly. Clinical Endocrinology 2001 55 183-189.
    • (2001) Clinical Endocrinology , vol.55 , pp. 183-189
    • Epaminonda, P.1    Porretti, S.2    Cappiello, V.3    Beck-Peccoz, P.4    Faglia, G.5    Arosio, M.6
  • 7
    • 4544253068 scopus 로고    scopus 로고
    • Pharmacological therapy for acromegaly. A critical review
    • Muller AF & van der Lely AJ. Pharmacological therapy for acromegaly. A critical review. Drugs 2004 16 1817-1838.
    • (2004) Drugs , vol.16 , pp. 1817-1838
    • Muller, A.F.1    van der Lely, A.J.2
  • 13
    • 0029922510 scopus 로고    scopus 로고
    • Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: Six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group
    • Giusti M, Gussoni G, Cuttica CM & Giordano G. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group. Journal of Clinical Endocrinology and Metabolism 1996 81 2089-2097.
    • (1996) Journal of Clinical Endocrinology and Metabolism , vol.81 , pp. 2089-2097
    • Giusti, M.1    Gussoni, G.2    Cuttica, C.M.3    Giordano, G.4
  • 15
    • 0033291744 scopus 로고    scopus 로고
    • Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group
    • Lancranjan I & Atkinson AB. Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group. Pituitary 1999 1 105-114.
    • (1999) Pituitary , vol.1 , pp. 105-114
    • Lancranjan, I.1    Atkinson, A.B.2
  • 18
    • 17744392005 scopus 로고    scopus 로고
    • Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly
    • Selvarajah D, Webster J, Ross R & Newell-Price J. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. European Journal of Endocrinology 2005 152 569-574.
    • (2005) European Journal of Endocrinology , vol.152 , pp. 569-574
    • Selvarajah, D.1    Webster, J.2    Ross, R.3    Newell-Price, J.4
  • 21
    • 22744440925 scopus 로고    scopus 로고
    • Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy
    • Jaquet P, Gunz G, Saveanu A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Enjalbert A & Culler MD. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. European Journal of Endocrinology 2005 153 135-141.
    • (2005) European Journal of Endocrinology , vol.153 , pp. 135-141
    • Jaquet, P.1    Gunz, G.2    Saveanu, A.3    Dufour, H.4    Taylor, J.5    Dong, J.6    Kim, S.7    Moreau, J.P.8    Enjalbert, A.9    Culler, M.D.10
  • 22
    • 0034493775 scopus 로고    scopus 로고
    • Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration
    • Jenkins PJ, Akker S, Chew SL, Besser GM, Monson JP & Grossman AB. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration. Clinical Endocrinology 2000 53 719-724.
    • (2000) Clinical Endocrinology , vol.53 , pp. 719-724
    • Jenkins, P.J.1    Akker, S.2    Chew, S.L.3    Besser, G.M.4    Monson, J.P.5    Grossman, A.B.6
  • 23
    • 0034123755 scopus 로고    scopus 로고
    • Variable growth hormone profiles following withdrawal of long-term 30 mg slow-release lanreotide treatment in acromegalic patients: Clinical implications
    • Caron P, Tabarin A, Cogne M, Chanson P & Jaquet P. Variable growth hormone profiles following withdrawal of long-term 30 mg slow-release lanreotide treatment in acromegalic patients: clinical implications. European Journal of Endocrinology 2000 142 565-571.
    • (2000) European Journal of Endocrinology , vol.142 , pp. 565-571
    • Caron, P.1    Tabarin, A.2    Cogne, M.3    Chanson, P.4    Jaquet, P.5
  • 24
    • 33747374573 scopus 로고    scopus 로고
    • Spanish-Portuguese Multicentre Autogel Study Group on acromegaly. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: A phase III trial
    • Lucas T & Astorga R. Spanish-Portuguese Multicentre Autogel Study Group on acromegaly. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial. Clinical Endocrinology 2006 65 320-326.
    • (2006) Clinical Endocrinology , vol.65 , pp. 320-326
    • Lucas, T.1    Astorga, R.2
  • 26
    • 4143086978 scopus 로고    scopus 로고
    • Systematic dose-extension of octreotide LAR: The importance of individual tailoring of treatment in patients with acromegaly
    • Turner HE, Thornton-Jones VA & Wass JA. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly. Clinical Endocrinology 2004 61 224-231.
    • (2004) Clinical Endocrinology , vol.61 , pp. 224-231
    • Turner, H.E.1    Thornton-Jones, V.A.2    Wass, J.A.3
  • 28
    • 0032922259 scopus 로고    scopus 로고
    • Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR)
    • Stewart PM, Stewart SE, Clark PM & Sheppard MC. Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR). Clinical Endocrinology 1999 50 295-299.
    • (1999) Clinical Endocrinology , vol.50 , pp. 295-299
    • Stewart, P.M.1    Stewart, S.E.2    Clark, P.M.3    Sheppard, M.C.4
  • 29
    • 0034974291 scopus 로고    scopus 로고
    • Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly
    • Colao A & Ferone D. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. Journal of Clinical Endocrinology and Metabolism 2001 86 2779-2786.
    • (2001) Journal of Clinical Endocrinology and Metabolism , vol.86 , pp. 2779-2786
    • Colao, A.1    Ferone, D.2
  • 30
    • 33745794539 scopus 로고    scopus 로고
    • Acromegaly: Molecular expression of somatostatin receptors subtypes and treatment outcome
    • Bronstein MD. Acromegaly: molecular expression of somatostatin receptors subtypes and treatment outcome. Frontiers of Hormone Research 2006 35 129-134.
    • (2006) Frontiers of Hormone Research , vol.35 , pp. 129-134
    • Bronstein, M.D.1
  • 32
    • 23244442834 scopus 로고    scopus 로고
    • Treatment of acromegaly with octreotide -LAR extensive experience in a Brzilian institution
    • Jallad RS, Musolino NR, Salgado LR & Bronstein MD. Treatment of acromegaly with octreotide -LAR extensive experience in a Brzilian institution. Clinical Endocrinology 2005 63 168-175.
    • (2005) Clinical Endocrinology , vol.63 , pp. 168-175
    • Jallad, R.S.1    Musolino, N.R.2    Salgado, L.R.3    Bronstein, M.D.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.